**Core tip:** The regulation and clinical disturbances of body fluid and its compartments are traditionally consigned to two concepts. The concept of tonicity of body fluids is critical in the regulation of the volume of body cells. Disturbances in tonicity result from abnormalities in the relation between body water and body solute. The concept of extracellular volume plays a critical role in the regulation of perfusion of body cells and organs. Disturbances in extracellular volume result primarily from abnormalities in sodium salt balance. Various methods for measuring body water and extracellular volume have been extensively applied in clinical practice. However, precise determination of the optimal body fluid volumes encounters difficulties which are greatly accentuated in severe illnesses, because several other factors interacting with extracellular volume in determining tissue perfusion, including cardiac output, capacity of the blood vessels, and Starling forces, are significantly altered in these illnesses. The aforementioned factors cause changes in the extracellular volume and create the need for optimal levels of this volume that are higher than those of healthy individuals and the need for newer methods for evaluating body fluid volumes. Thus, fluid regulation in severe illness represents an evolving concept of body fluid balance separate from the two traditional concepts. Important questions about this third concept remain unanswered underscoring the need for further research.

INTRODUCTION
============

Fluid balance is critical in health\[[@B1]\] and disease\[[@B2],[@B3]\]. Its management is required in a variety of instances. These include stress that healthy individuals may experience at certain times, *e.g*., during intense exercise\[[@B4]\], development of various acute or chronic diseases\[[@B5]-[@B7]\], and complication of the course of several diseases\[[@B3],[@B8],[@B9]\]. Proper fluid balance is a key management target for groups of individuals experiencing difficulties in maintaining normalcy with regard to it, *e.g*., those with cognition disorders\[[@B10]\], the very young\[[@B11],[@B12]\], and the very old\[[@B13],[@B14]\]. Less well known is the fact that disorders of fluid balance are encountered in conditions common in the general population, *e.g*., obesity\[[@B15]\] or hypertension\[[@B16]-[@B18]\].

Distinguishing normal from abnormal fluid balance in one's medical practice can be challenging. The diagnosis of fluid balance abnormalities requires the informed and reasoned interpretation of clinical and laboratory information\[[@B14],[@B19]\]. However, few would argue with the contention that the diagnostic accuracy of these methods is weak in general\[[@B14],[@B19]-[@B21]\] and is further complicated by the indiscriminate and inappropriate use of terms when expressing aspects of fluid balance. For example, the terms "hydration", "dehydration", and "overhydration" are often loosely used to express not one, but two fluid balance concepts, specifically body water balance and extracellular volume (ECFV) balance\[[@B22],[@B23]\]. The need to distinguish between pure water deficit and ECFV depletion has been stressed in the literature\[[@B24]-[@B26]\]. The use of the term "dehydration" to indicate water deficit or ECFV depletion causes confusion among health care practitioners\[[@B27]\].

The traditional approach to understanding disorders of fluid balance has been to compare measured or estimated TBW and ECFV between the patients being studied and the corresponding "normal" values. However, this approach has three limitations: First, identifying "normal values" is fraught with ambiguity. Second, abnormalities in TBW and ECFV often coexist. Finally, optimal values of TBW and especially ECFV differ considerably between patients with serious illnesses *vs* normal individuals. This last difference justifies the introduction of a third approach to fluid balance, namely fluid balance in severe illness. Our aim in this report is to review the methods of measuring TBW and ECFV, the uses and limitations of these methods, and the methods of evaluating fluid balance in patients with severe illness.

BODY FLUID BALANCE AS A FUNCTION OF WATER BALANCE
=================================================

Parameters characterizing water balance
---------------------------------------

The concept of water balance as applied in clinical practice refers to the relationship between total TBW and body solute. Osmolality, which expresses the total solute concentration in a fluid, is the core parameter of this concept\[[@B28]\]. The principal physiologic function that depends on this first fluid balance concept is the maintenance of stable volume of the body cells. Stable body cell volume is critical for cell function and survival and is based on two membrane-related phenomena, active solute transport mechanisms of the cell membranes, mainly mediated by sodium-potassium ATPase, and high permeability of cell membranes to water\[[@B29]\]. This second process has two fundamental consequences: (1) Osmolality is equal between the intracellular and extracellular compartment in the steady state\[[@B30]\]; and (2) the distribution of TBW between the intracellular and extracellular compartments is determined by the total solute in each compartment\[[@B31]\].

Certain solutes dissolved in body fluids are distributed almost exclusively in the intracellular or the extracellular compartment, while other solutes are distributed in TBW. Changes in the amount of solutes distributed in TBW (urea, ethanol, and other alcohols, *e.g*., methanol and propyl alcohol) will lead to parallel changes in osmolality of all body fluids, but will not cause any change in cell volume. In contrast, changes in the amount of solutes distributed, by and large, in one of the two major body fluid compartments will lead to parallel changes in body fluid osmolality and opposite sign changes in cell volumes. For example, a decrease in the amount of an extracellular solute causes a decrease in body fluid osmolality and an increase in cell volume.

Tonicity is the portion of osmolality contributed by solutes distributed in one major body fluid compartment\[[@B29]\]. The terms "hypotonicity" and "hypertonicity" should be used to denote, respectively, relative excess or relative deficit of water in place of the ambiguous terms "overhydration" and "dehydration". Serum sodium concentration (\[Na\]~S~) is the most widely applied index of tonicity and is accurate except when there is an excess of exogenous extracellular solutes, other than sodium salts, or in the presence of falsely low laboratory values of \[Na\]~S~ (pseudohyponatremia) resulting from measurement of \[Na\]~S~ by indirect potentiometry when serum water fraction is decreased secondary to an increase in serum solid (proteins or lipids) concentration\[[@B32]\].

Determinants of body fluid tonicity
-----------------------------------

The quantitative approach to clinical aspects of the first concept of fluid balance is based on the pivotal work of Edelman et al\[[@B33]\]. These researchers established the relationship between solutes involved in the function of tonicity and TBW using dilution of radio-isotopic markers in various clinical states potentially associated with dystonicity. Their work established the fact that \[Na\]~S~ represents the fraction: Sum of exchangeable sodium plus exchangeable potassium over body water\[[@B33]\]. A simplified expression of this fraction, used extensively in treating disorders of tonicity is as follows: \[Na\]~S~ = (Exchangeable Na + Exchangeable K)/TBW. In this fraction, exchangeable sodium represents the extracellular solute while exchangeable potassium represents the intracellular solute\[[@B29]\]. Abnormal values of the measured \[Na\]~S~, or serum osmolality, or of serum tonicity calculated as the sum of the osmotic equivalents of \[Na\]~S~ plus serum glucose concentration\[[@B34]\], indicate that there is a discrepancy between TBW and effective body solute; however, they provide no information about excesses or deficits of any of the particular determinants of tonicity. In fact, TBW may be low, normal, or excessive in patients with either hypertonicity\[[@B34]-[@B37]\] or hypotonicity\[[@B38]-[@B43]\]. Figure [1](#F1){ref-type="fig"} shows changes in extracellular and intracellular volumes in euvolemic, hypovolemic and hypervolemic hyponatremia.

![Body compartment volume (L) in the three categories of hyponatremia. I: Normal state: ECFV = 16 L, ICFV = 24 L, serum sodium concentration (\[Na\]~S~) = 140 mmol/L. II: Hypovolemic hyponatremia; IIa: Loss of 8 L of isotonic sodium solution: ECFV = 8 L, ICFV = 24 L, \[Na\]~S~ = 140 mmol/L; IIb: Gain of 8 L of water; ECFV = 10 L, ICFV = 30 L, \[Na\]~S~ = 112 mmol/L. III: Hypervolemic hyponatremia; IIIa: Gain of 8 L of isotonic sodium solution; ECFV = 24 L, ICFV = 24 L, \[Na\]~S~ = 140 mmol/L; IIIb: Gain of 8 L of water; ECFV = 28 L, ICFV = 28 L, \[Na\]~S~ = 120 mmol/L. IV: Euvolemic hyponatremia manifested in the syndrome of Inappropriate ADH secretion, which combines water gain and sodium loss\[[@B38],[@B39]\]; IVa: Gain of 8 L of water; ECFV = 19.2 L, ICFV = 28.8 L, \[Na\]~S~ = 116.7 mmol/L; IVb: Loss of 560 mmol of monovalent sodium salt (*e.g*., NaCl); ECFV = 16 L, ICFV = 32 L, \[Na\]~S~ = 105 mmol/L. ECFV: Extracellular fluid volume; ICFV: Intracellular fluid volume.](WJN-7-1-g001){#F1}

Establishing the presence and degree of excess or deficit of the components that determine tonicity is critical for the rational management of disorders of tonicity. Assessing body water balance is the first step in the management of tonicity disturbances. A detailed review of the physiology and pathophysiological disturbances of body water is beyond the scope of this report; however, Schrier has provided an insightful review of this topic\[[@B44]\]. Determining whether TBW is abnormal or not in a patient presenting with dystonicity requires a comparison of this patient's TBW and the "normal" value of TBW.

Measuring body water
--------------------

"Normal" TBW values were first established as the weight differences between fresh and desiccated animal carcasses\[[@B45]\]. Subsequently, TBW was measured by dilution of injected markers. Elkington and Danowski provide a useful explanation of this methodology\[[@B46]\]. The TBW markers most widely applied in research studies include tritiated water (^3^H~2~O)\[[@B47]\], deuterium oxide-heavy water-(^2^H~2~O)\[[@B48]\] and antipyrine\[[@B49]\]. Other markers, *e.g*., urea, thiourea and ethanol, have enjoyed only limited application. Heavy water does not subject patients to radiation and is the main reference method for measuring TBW\[[@B50],[@B51]\]. Water labeled with the stable oxygen isotope ^18^O (H~2~^18^O) has also been used to estimate TBW\[[@B52]\]. Both tracer hydrogen (^2^H) and tracer oxygen (^18^O) exchange with various compounds in the body, thereby causing small overestimates of body water by dilution of ^2^H~2~O or measurement of H~2~^18^O. Hydrogen of water molecules exchanges with labile protons in protein molecules, while oxygen of water molecules exchanges into inorganic pools during formation of ester bonds\[[@B53]\]. Since the rate of exchange of ^2^H with nonaqueous hydrogen slightly exceeds the rate of exchange of ^18^O with nonaqueous oxygen in body tissues, body water estimates from ^2^H~2~O dilution space are approximately 3.5% higher than those obtained using H~2~^18^O\[[@B53]\].

Efforts to develop non-invasive measurements of TBW applicable to clinical states have applied newer techniques that target body composition; these include: Dual-energy X-ray absorptiometry (DEXA)\[[@B54]\], air displacement plethysmography\[[@B55]\], nuclear magnetic resonance spectroscopy\[[@B56]\], and bioelectrical impedance analysis (BIA)\[[@B57]-[@B59]\]. This last technique is relatively inexpensive and simple to use. Because of these advantages, BIA has been extensively applied in clinical settings requiring precise knowledge of the state of water balance, *e.g*., in populations on chronic dialysis. The newer methods\[[@B54]-[@B57]\] estimate TBW using empirical equations derived from comparisons of their measurements to measurements made using reference methods. The reliability of these newer methods depends on the accuracy of certain assumptions made during construction of the equations\[[@B60],[@B61]\]. Findings from these techniques may disagree in subjects who do not fulfill the assumptions on which these equations are based\[[@B62]\].

Comparisons by statistical regression methods of measurements of TBW by reference methods to known factors affecting body composition has led to the development of anthropometric formulas estimating TBW as a function of height, body weight, age, gender and ethnicity in subjects with normal water balance. Of these formulas, three have been extensively used in adults\[[@B63]-[@B65]\] and one in children\[[@B66]\]. Figure [2](#F2){ref-type="fig"} shows TBW values derived using the tree formulas for adults, which provide comparable values of body water in most cases\[[@B67]\]. Estimates from one of these formulas should provide more acceptable values of TBW than the older methods used to estimate TBW for the computation of the volume of the replacement fluids in dystonicity states. These older methods accounted only for body weight and gender; for example, TBW was computed as 0.6 of body weight in men and 0.5 of body weight in women. However, the existing anthropometric formulas can give misleading results for several reasons. The first source of inaccuracy is that they do not account for all the determinants of body composition. The degree of obesity varies substantially between subjects with the same height, age, gender, ethnicity and body weight. The anthropometric formulas will compute the same value of TBW for all these subjects. However, since body fat contains minimal amounts of water, TBW is less in obese than lean subjects with the same anthropometric characteristics. This is evident in the large standard errors of these formulas, which suggest a potential variation of several liters of estimates of TBW in subjects with the same age, height, weight, and ethnicity, and no water balance abnormalities.

![Total body water estimates from anthropometric formulas. Estimates of total body water computed by the Hume et al\[[@B63]\], Watson et al\[[@B64]\] and Chumlea et al\[[@B65]\] anthropometric formulas for men and women with the same age (40 years) and varying height and weight. AA: African American; C: Caucasians.](WJN-7-1-g002){#F2}

A second source of inaccuracy of the anthropometric formulas is the presence of abnormal water balance, which creates the potential of even greater error of the formulas. Gains or losses of water result in equal magnitude gains or losses in body weight. The coefficients assigned to body weight in anthropometric formulas can be used to predict the direction of their error in subjects with water balance abnormalities. These coefficients are substantially lower than 0.5 L/kg in all formulas resulting in decreasing values of body water content (the fraction TBW over body weight) as weight increases and increasing values of water content as weight decreases\[[@B68]\]. These changes in water content are appropriate for subjects with increasing weight due to obesity or decreasing weight due to loss of body fat\[[@B68]\]. However, body water content mathematically increases in subjects gaining weight because of fluid retention and decreases in subjects losing body fluids\[[@B69],[@B70]\]. The Chertow anthropometric formula\[[@B71]\] was derived from measurements of TBW pre-hemodialysis, when patients routinely present with fluid gains. This formula provides higher estimates of TBW than the other anthropometric formulas\[[@B67]\]. In addition, the Chertow formula accounts for one determinant of body composition (diabetes mellitus) not included in the other formulas\[[@B63]-[@B65]\], and contains coefficients that take into consideration interactions between age and gender, age and weight, and height and weight\[[@B71]\]. The main drawback of the Chertow formula is that it computes TBW for only the average fluid gain in the dialysis population that is being studied. Johansson et al\[[@B72]\] developed anthropometric formulas estimating TBW in peritoneal dialysis patients. Table [1](#T1){ref-type="table"} shows the anthropometric formulas estimating TBW in normal adults, normal children and patients on dialysis.

###### 

Anthropometric formulas estimating body water

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Adults, normal body water values
  Hume and Weyers formulae\[[@B63]\]
  Women: TBW = -35.270121 + 0.344547H + 0.183809W
  Men: TBW = -14.012934 + 0.194786H + 0.296785W
  Watson et al\[[@B64]\] formulae
  ....Women: TBW = -2.097 +0.1069H + 0.2466W
  Men: TBW = 2.447 - 0.09516A + 0.1074H + 0.3362W
  Chumlea et al\[[@B65]\] formulae
  Women, African American: TBW = -16.71 - 0.05A + 0.24H + 0.22W
  Women, Caucasian: TBW = -10.50 - 0.01A + 0.18H + 0.20W
  Men, African American: TBW = -18.37 - 0.09A + 0.25H + 0.34W
  Men, Caucasian: TBW = 23.04 - 0.03A + 0.50W - 0.62BMI
  Children, normal body water values
  Mellits, Cheek formulae\[[@B66]\]
  Girls, H ≤ 110.8 cm: TBW = 0.076 + 0.013H + 0.507W
  Girls, H \> 110.8 cm: TBW = -10.313 + 0.154H + 0.252W
  Boys, H ≤ 132.7 cm: TBW = -1.927 + 0.045H + 0.465W
  Boys, H \> 132.7 cm: TBW = -21.993 + 0.209H + 0.465W
  Adults, pre-hemodialysis
  Chertow et al\[[@B71]\] formula
  TBW = 0.07493713A - 1.01767992G + 0.57894981D + 0.12703384H - 0.04012056W - 0.00067247W2 - 0.03486146 (A × G) + 0.11262857 (G × W) + 0.00104135 (A × W) + 0.00186104 (H × W)
  Adults, peritoneal dialysis
  Johansson et al\[[@B72]\] formulae
  Women: TBW = -29.994 - 0.004A + 0.294H + 0.214W
  Men: TBW = -10.759 - 0.078A + 0.192H + 0.312W
  .... All patients: TBW = -42.879 - 0.033A + 0.372H + 0.274W
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Note that the Watson formula for men has an age term while the Watson formula for women has no age term. Age effects on body water are more pronounced in men than in women. This is clearly indicated by the coefficients for age in the Chumlea and Johansson formulas. TBW: Total body water (L); H: Height (cm); A: Age (yr); BMI: Body mass index (kg/m^2^); G: Gender (male = 1, female = 0); D: Diabetes (present = 1, absent = 0).

Determining whether there is water excess or water deficit in an individual patient, regardless of tonicity issues, can be challenging. Analyses of the components of body composition\[[@B73]\] have the potential to reveal whether TBW is normal or not. According to Siri's simplest model of body composition\[[@B74]\], the body has two components: Fat and fat-free mass. Body water occurs almost exclusively in the fat-free mass component. When the water balance is normal, the water content of fat-free mass is at or very close to 73%\[[@B75]-[@B77]\]. Thus, determining whether TBW is within the normal range or not requires measurement of both fat-free mass and TBW.

Methods for measuring TBW and their limitations were discussed previously in this report. Fat-free mass is routinely measured by BIA or DEXA; however, these methods have hidden drawbacks. For example, an important assumption of the DEXA measurement of fat-free mass is that it contains 73% water\[[@B60]\]. The measurement of fat-free mass by reference methods, *e.g*., measurement of total body potassium (TBK) in a total body counter\[[@B78]\], is generally not available for routine clinical practices. Therefore, measuring TBW accurately and determining whether body water content is normal or not in individual patients require further research efforts.

Treatment of dystonicity states
-------------------------------

Hyperglycemic crises are associated with hypertonicity and severe deficits of body water, sodium, potassium, and other electrolytes\[[@B79]\]. The principles and quantitative aspects of treatment of these crises are detailed in several reports\[[@B37],[@B79]-[@B81]\]. Herein we will present the principles of management of true (hypotonic) hyponatremia\[[@B43]\] and hypernatremia\[[@B37]\].

Extensive guidelines delineating the treatment of hypotonic hyponatremia have been published recently\[[@B82],[@B83]\]. Treatment is guided by the severity and the pathophysiologic mechanism of hyponatremia\[[@B43]\]. Severe cases with profound hyponatremia or symptoms attributed to it require infusion of hypertonic saline. The infused volume of saline is determined by formulas. The Adrogué-Madias formula\[[@B41]\] has been successfully used to guide the treatment of hyponatremias. This formula calculates the increase in \[Na\]~S~ after infusion of one liter of saline with sodium concentration higher than that in the serum and accounts for the original \[Na\]~S~, the sodium concentration of the infusate, the original TBW and the volume of the infusate. A formula for calculating the volume of hypertonic saline required to raise \[Na\]~S~ to a desired value, based on the same principles as the Adrogué-Madias formula, was published subsequently\[[@B84]\]. These two formulas are shown in Table [2](#T2){ref-type="table"}\[[@B41],[@B84]\].

###### 

Formulas for treatment of dysnatremias with saline or water infusions

  ---------------------------------------------------------------------------------------------------------
  Hypotonic hyponatremia
  Change in sodium concentration after infusion of 1 L of saline. Adrogué-Madias formula\[[@B41]\]:
  \[Na\]~Final~ - \[Na\]~Initial~ = (\[Na\]~Infusate~ - \[Na\]~Initial~)/(TBW~Initial~ + 1)
  Volume of saline required for a targeted serum sodium concentration\[[@B84]\]:
  V~Infusate~ = TBW~Initial~ × (\[Na\]~Targeted~ - \[Na\]~Initial~)/\[Na\](~Infusate~ - \[Na\]~Targeted~)
  Hypernatremia
  Volume of D5/W required for a targeted serum sodium concentration\[[@B37]\]:
  V~Infusate~ = TBW~Initial~ × (\[Na\]~Initial~ - \[Na\]~Targeted~)/\[Na\]~Targeted~
  Volume of hypotonic saline required for a targeted serum sodium concentration\[[@B37]\]:
  V~Infusate~ = TBW~Initial~ × (\[Na\]~Initial~ - \[Na\]~Targeted~)/(\[Na\]~Targeted~ - \[Na\]~Infusate~)
  ---------------------------------------------------------------------------------------------------------

\[Na\]~Final~: Final serum sodium concentration after infusion of 1 L of saline with a sodium concentration higher than the initial serum sodium concentration; \[Na\]~Initial~: Initial serum sodium concentration; \[Na\]~Infusate~: Sodium concentration in the infused saline; TBW~Initial~: Initial volume of body water; V~Infusate~: Volume of infused saline or dextrose required for a targeted change in serum sodium concentration; \[Na\]~Targeted~: Targeted value of serum sodium concentration.

General therapeutic measures applicable to all hypotonic hyponatremias include restriction of fluid intake and steps directed towards increasing renal water excretion, such as administration of loop diuretics or solute (salt tablets, urea)\[[@B43]\]. Specific interventions for the management of hyponatremia are predicated on the pathophysiologic mechanism of the condition, and include: (1) Isotonic saline infusion to restore the ability of the kidneys to excrete large volumes of water in hypovolemic hyponatremia; (2) vasopressin 2 (V2) receptor antagonists to restore the renal diluting capacity in the Syndrome of Inappropriate Antidiuretic Hormone secretion (SIADH); and (3) available specific treatments to correct conditions causing hyponatremia\[[@B43]\].

The osmotic demyelination syndrome can result from too rapid correction of hyponatremia. To prevent the development of this syndrome, the general aim of treatment is to achieve a maximal increase in \[Na\]~S~ equal to 6 mmol/L over 24-h. Exceptions to this recommendation are cases with persistence of severe clinical manifestations from hyponatremia, when an even greater rate of increase in \[Na\]~S~ is required\[[@B43]\]. In certain circumstances, foremost after restoration of the urinary diluting capacity during correction of hypovolemic hyponatremia by adequate volume replacement or after correction of SIADH by administration of V2 receptor antagonists, dangerous rises in \[Na\]~S~ can develop. Frequent measurement of \[Na\]~S~, *e.g*., every 2 to 4 h, and, in selected cases, of urine flow rate and urine sodium and potassium concentrations, is critical for prevention of osmotic demyelination\[[@B85]\]. Prevention of formation of large volumes of dilute urine by infusion of desmopressin can prevent excessive rises in \[Na\]~S~ in patients in whom correction of the condition causing the hyponatremia, *e.g*., SIADH or hypovolemia, restores the urinary diluting mechanism\[[@B86],[@B87]\].

Hypernatremia is correctable by infusion of either water in the form of 5% dextrose solution or, if hypovolemia is present, hypotonic saline. Formulas used to calculate the volumes of water or hypotonic saline required to obtain the desired decrease in \[Na\]~S~ are based on the same principles as those used to treat hyponatremia\[[@B37]\]. Table [2](#T2){ref-type="table"} shows these formulas. Too rapid decline in \[Na\]~S~ increases the risk of severe neurological manifestations\[[@B37]\].

Clinicians should be aware that in addition to the occasional uncertainty associated with estimating TBW by means of formulas, formulas for calculating infusion volumes for treating dysnatremias carry several other potential sources of error\[[@B42],[@B43]\]. These formulas do not account for changes in the determinants of \[Na\]~S~ during treatment, such as water and electrolyte losses in the urine during treatment\[[@B37],[@B84],[@B85]\], potential release of sodium stored in interstitial glycosaminoglycan (GAG) networks\[[@B88]\], and changes in intracellular organic osmolytes\[[@B89]\]. For these reasons, changes in \[Na\]~S~ during treatment of dysnatremia must be monitored. Clarification of the quantitative impact of these other determinants on changes in \[Na\]~S~ during treatment of dysnatremias could lead to the development of more accurate predictive formulas. However, accurate prediction of the magnitude of urinary losses of water, sodium and potassium is exceedingly difficult. Monitoring of the clinical status of the patients and frequent measurements of \[Na\]~S~ will remain the critical step of the treatment of all dysnatremias treated with saline or dextrose solutions\[[@B43],[@B84],[@B85],[@B88],[@B89]\]. Water bound to hydrophilic surfaces\[[@B90]\] is another elusive factor that can complicate the treatment of dystonicity using quantitative tools. However, the extent to which changes in tonicity alter the binding of water to hydrophilic surfaces is poorly understood and invites further investigation.

BODY FLUID BALANCE AS A FUNCTION OF EXTRACELLULAR FLUID VOLUME
==============================================================

When a body fluid abnormality secondary to a disturbance in ECFV is diagnosed, the terms "hypovolemia" and "hypervolemia" should be used instead of the ambiguous terms "dehydration" of "overhydration", respectively. The regulation of ECFV is a critical body function.

Determinants of extracellular fluid volume
------------------------------------------

The three determinants of ECFV are TBW, total intracellular solute, and total extracellular solute. As noted earlier, TBW is partitioned between the intracellular and extracellular spaces in proportion to the amount of solute in each compartment. Changes in TBW unaccompanied by changes in solute will cause opposite changes in tonicity and in the volumes of body fluid compartments. An isolated gain in TBW will cause hypotonicity and hypervolemia in both the intracellular and extracellular compartments while an isolated loss of body water will have exactly the opposite effects. Abnormal gains in intracellular solute causing body fluid shifts into the intracellular compartment can be observed in serious disease states leading to cellular sodium gain, such as occur in patients with "sick cell syndrome"\[[@B91]\]. Significant losses of intracellular solute, *i.e*., potassium, are associated with fluid shifts into the extracellular compartment and hyponatremia\[[@B92]\]. Large potassium losses, such as occur secondary to diuretics, may be associated with loss of extracellular solute and hypovolemia.

Most clinical ECFV disturbances are caused by changes in extracellular solute. Thus, the amount of solute in the extracellular compartment is critical in any analysis of factors affecting ECFV. Sodium salts, including sodium chloride and to a lesser degree sodium bicarbonate, constitute 90% or more of the extracellular solute. In a real sense, sodium chloride defines ECFV and abnormalities in sodium salt balance are the major sources of ECFV disturbances\[[@B22]\]. Gain in extracellular solutes other than sodium salts (*e.g*., glucose) can also cause ECFV expansion. The kidneys are the end-organ that regulate ECFV. Complex circulatory and neuro-endocrine mechanisms play vital roles in this regulation, which has attracted a major part of the research in renal transport and excretion mechanisms in health and disease\[[@B93]-[@B95]\]. Regulation of sodium is a high priority renal function. In various clinical conditions stimulating the renal mechanisms for sodium retention (*e.g*., hypovolemia, cardiac failure, cirrhosis, *etc*.), potassium balance, acid-base balance and water balance are sacrificed to preserve body sodium. Renal tubular sodium transport processes account for the largest fraction of oxygen consumption in the kidneys\[[@B96]\]. Details of the regulation of sodium balance are beyond the scope of this report.

Measuring extracellular fluid volume
------------------------------------

Measurement of ECFV entails ambiguities exceeding those associated with the measurement of TBW. These ambiguities relate to both the concept of ECFV and the methods for measuring it. The conceptual difficulty is rooted in the definition of extracellular space. Intracellular space is defined as the space enclosed within the cell membranes and intracellular water is the portion of body water in the intracellular space. However, there is significant doubt whether all body fluid compartments outside the cell membranes should be considered as contributing to the ECFV. The fluid compartments in question, which were termed by Moore as the transcellular fluids\[[@B97]\], include fluids in the gastrointestinal tract\[[@B98]\], collagenous connective tissues\[[@B99]\], serous and synovial cavities\[[@B46]\], cerebrospinal space\[[@B46]\], lower urinary tract\[[@B46]\], and bile ducts \[[@B46]\].

Measurement of ECFV by dilution of injected exogenous markers, *e.g*., radioactive compounds\[[@B100]\], added to the difficulties. Table [3](#T3){ref-type="table"} lists some of these markers\[[@B46],[@B101]-[@B113]\]. Several "extracellular" markers penetrate transcellular fluids and some, including the commonly used bromide salts, enter partially into the intracellular compartment\[[@B46]\]. Consequently, there are substantial differences in the estimates of ECFV between these markers\[[@B46]\].

###### 

Measurement of extracellular volume by tracer dilution

  **Extracellular marker**         **Ref**.
  -------------------------------- -------------
  Inulin                           \[101\]
  Sucrose                          \[102\]
  Thiosulfate                      \[103,104\]
  Mannitol                         \[105\]
  Radiosulfate (S^35^)             \[106,107\]
  Bromide                          \[108,109\]
  Radiochloride (Cl^38^, Cl^36^)   \[109,110\]
  Stable chloride (Cl^35^)         \[111\]
  Radiosodium (Na^24^)             \[112\]
  Thiocyanate                      \[113\]

Recently, several new technologies for measuring ECFV have been developed\[[@B114]\]. Table [4](#T4){ref-type="table"} shows the principal techniques, which fall into the following three categories: (1) methods based on body composition, including BIA\[[@B115]-[@B121]\] or bioelectrical impedance vector analysis (BIVA)\[[@B122],[@B123]\], DEXA\[[@B124]-[@B132]\], and magnetic resonance imaging (MRI)\[[@B133]\]; (2) simultaneous measurement of TBK in a total body counter measuring stable potassium (^40^K) and TBW usually by ^2^H~2~O dilution\[[@B134]-[@B136]\]; and (3) estimation of glomerular filtration rate (GFR) using exogenous markers with extracellular distribution\[[@B137]-[@B147]\]. The ECFV value is computed in the third category by either constant infusion\[[@B138]\], or, more often, a single injection\[[@B139]\] of the exogenous GFR marker. In the case of a single injection, the theoretical equilibrated initial concentration of the marker in the extracellular fluid is calculated by extrapolating its plasma disappearance curve to zero time (time of infusion of the marker)\[[@B139]\].

###### 

Measurement of extracellular volume by newer methods

  **Methodology**                                                    **Ref**.
  ------------------------------------------------------------------ -------------
  Methods evaluating body composition                                
  Bioelectrical impedance, bioelectrical impedance vector analysis   \[115-123\]
  Dual-energy X-ray absorptiometry                                   \[124-132\]
  Magnetic resonance imaging                                         \[133\]
  Methods measuring total body water and intracellular volume        
  Simultaneous measurement of total body water and potassium         \[134-136\]
  Methods using GFR markers                                          
  Inulin                                                             \[138,139\]
  Polyfructosan                                                      \[140\]
  51cromium ethylenediamine tetra-acetic acid (^51^Cr- EDTA)         \[141-143\]
  Iohexol                                                            \[144\]
  Technetium diethylene triamine penta-acetic acid (^99^mTC-DTPA)    \[145,146\]
  Iothalamate                                                        \[147\]

GFR: Glomerular filtration rate.

The methodologies for measuring TBW and ECFV by these newer techniques were developed by comparing their performance to measurements from the older dilution techniques, mostly the ^2^H~2~O and bromide dilution techniques\[[@B116],[@B117],[@B126],[@B130],[@B134],[@B148]-[@B156]\]. Figure [3](#F3){ref-type="fig"} shows average ECFV values obtained by the older dilution techniques (Table [3](#T3){ref-type="table"}) and several frequently used newer techniques (Table [4](#T4){ref-type="table"}). The values resulting from the most commonly used newer techniques (BIA, DEXA) are, in most cases, close to those based on chloride or bromide space. Equations predicting normal ECFV values from simple anthropometric measurements, for example as a fraction of body weight, were developed using ECFV measurements by one of the newer methods\[[@B144],[@B157]\]. However, these equations are not accurate in patients with ECV disturbances. Finally, techniques for measuring ECFV in diseased organs or tissues, for example in malignant tumor-bearing organs, have also been developed\[[@B158]-[@B160]\].

![Average extracellular fluid volume estimates expressed as percentages of total body water. I-V: Tracer dilution estimates\[[@B46]\]; I: Sucrose, thiosulfate; II: Mannitol, sulfate; III: Bromide, chloride; IV: Sodium; V: Thiocyanate; VI-VII: Newer techniques; VI: Dual-energy X-ray absorptiometry\[[@B130]\]; VII: Bioelectrical impedance\[[@B115]\]; VIII: Simultaneous determination of total body potassium and total body water\[[@B195]\]; IX, X: Glomerular filtration rate markers; IX: Inulin\[[@B139]\]; X: Iothalamate\[[@B147]\]. ECFV: Extracellular fluid volume; TBW: Total body water.](WJN-7-1-g003){#F3}

Clinical applications of extracellular fluid volume estimates
-------------------------------------------------------------

The main clinical application of measurements of ECFV is in conditions requiring precise management of excesses or deficits of this volume. To quantify ECFV excess, Chamney et al\[[@B50]\] measured TBW by ^2^H~2~O dilution, ECFV by NaBr dilution, and body fat by DEXA and air-displacement. These investigators developed a quantitative model of body fluids containing three compartments: Normally hydrated lean tissue, normally hydrated adipose tissue, and excess fluid. Chronic dialysis for end-stage kidney disease represents an example of Chamney's three-body fluid compartment approach. One of the main aims of the prescription of hemodialysis is achieving "dry weight" by computing prior to each hemodialysis session the volume of fluid that should be removed to return ECFV within its normal range\[[@B161]\]. Although clinical criteria for ECFV excess or deficit are useful in monitoring the overall state of health of hemodialysis patients, they have low positive and negative predictive values and carry the risk of excessive volume removal and hypotension during a hemodialysis session. DEXA has been used to evaluate ECFV in a small number of studies\[[@B162]\]. BIA and BIVA studies are simple, technically easy to conduct, and inexpensive. Studies conducted in various parts of the world have provided evidence that measurements of ECFV by BIA or BIVA improve the management of fluid balance in hemodialysis patients\[[@B163]-[@B170]\].

Hyperglycemic crises represent another clinical state in which ECFV changes, along with changes in the relationship between TBW and body solute, cause severe clinical manifestations and play an important role in the prescription of fluid management\[[@B37]\]. ECFV changes occur during both development and treatment of severe hyperglycemia and differ between subjects with preserved and severely impaired renal function. The increase in extracellular solute during development of hyperglycemia causes intracellular water to shift into the extracellular compartment. This osmotic fluid shift, which affects the estimation of the serum tonicity\[[@B171]\], may cause volume overload symptoms in patients with advanced renal failure\[[@B172]\]. The calculation of the magnitude of this shift requires knowledge of the amount of glucose added to the extracellular compartment, in addition to Edelman's three determinants of \[Na\]~S~, which include body sodium, body potassium and TBW\[[@B173],[@B174]\]. The total amount of glucose in the body fluids is the product of the volume of distribution of glucose times the serum glucose concentration\[[@B37]\].

Calculations of body fluid spaces made after a single glucose injection in normal individuals reported a glucose volume of distribution that was within the range of normal ECFV values\[[@B175]-[@B177]\]. Insulin is usually the only treatment required for hyperglycemia in oligoanuric patients in whom correction of hyperglycemia reverses both hypertonicity and ECFV expansion\[[@B172]\]. The reciprocal changes in \[Na\]~S~ and serum glucose concentration during treatment of oligoanuric hyperglycemia with insulin only allow the calculation of the fraction ECFV/TBW at normoglycemia\[[@B178]\]. Calculation of this fraction in hyperglycemic patients at their "dry weight" yielded ECFV/TBW values within the normal range\[[@B178]\].

Both ECFV changes and tonicity differ in hyperglycemic patients with preserved renal function\[[@B81],[@B174],[@B179]\]. These patients manifest osmotic diuresis secondary to glycosuria during development of hyperglycemia. The fluid loss from osmotic diuresis causes ECFV contraction and rise in tonicity far exceeding the rise from extracellular glucose gain. ECFV losses persist during treatment if glycosuria persists\[[@B79]\]. In most cases, treatment of hyperglycemia in this patient group requires, in addition to insulin, infusion of large volumes of hypotonic saline and potassium salts and close monitoring of clinical status and laboratory values\[[@B37]\]. The volume and composition of the replacement solutions is determined empirically based on clinical manifestations and laboratory values. Selected cases where body weight measurements were recorded immediately before and during a hyperglycemic crisis allow more precise calculation of the volume and composition of the replacement solutions, but still require close monitoring\[[@B81]\].

In addition to chronic dialysis and hyperglycemia, ECFV abnormalities and the need to monitor ECFV and its changes during treatment have been investigated in a variety of chronic and acute illnesses\[[@B128],[@B154],[@B180]-[@B187]\]. Finally, another example of the potential clinical applications of ECFV and TBW measurements is in determining body composition. The components of body composition, particularly muscle mass and body fat, are major determinants of morbidity and mortality in the elderly, as well as in patients with various acute and chronic illnesses\[[@B188],[@B189]\]. Wang et al\[[@B190]\] developed sophisticated mathematical models of body composition using as their major parameter the ratio of extracellular to intracellular water. Measuring TBW and ECFV provides a reliable reference method for body composition analysis.

Limitations of extracellular fluid volume estimates
---------------------------------------------------

The efficacious application of measurements of ECFV in clinical practice relies on precise estimates of the normal values. Determination of the normal ECFV values has encountered significant limitations. The first limitation relates to the determination of the precision of ECFV measurement, which is established by frequent serial measurements\[[@B191]\]. Burke and Staddon measured repeatedly over a six-week period TBW by ^3^H~2~O dilution and ECFV by radiosulfate dilution in 10 healthy subjects\[[@B192]\]. These authors calculated a mean precision value of 2.63 L for TBW and 1.11 L for ECFV. The presence of disease raises an additional challenge to the precision of the ECFV measurements. Below we discuss the precision of three methods which have received extensive clinical applications: Namely chloride or bromide dilution, measurement of TBK and TBW, and BIA.

Estimates of ECFV based on chloride, or more frequently bromide, dilution are calculated as the fraction "amount of marker in the body" over "the equilibrated concentration of this marker in the extracellular fluid" and are routinely corrected for Gibbs-Donnan equilibrium and intracellular penetration of the markers\[[@B193]\]. The Gibbs-Donnan equilibrium states that due to electrostatic forces, the concentration of a crystalloid anion is higher in interstitial fluid than in serum, which is rich in colloidal anions (*i.e*., proteins)\[[@B29]\]. The extracellular chloride or bromide concentration is calculated by multiplying the serum concentration by an empiric Gibbs-Donnan coefficient, which is usually 1.050\[[@B193]\]. The magnitude of the error from this calculation in subjects with low plasma protein level or elevated interstitial protein concentration is unknown.

The calculated estimates of ECFV by bromide or chloride dilution are also corrected for intracellular penetration of the ECFV index by a reducing coefficient, usually 0.90\[[@B193]\]. Penetration of reference extracellular markers into the transcellular or intracellular compartment differs between healthy and severely ill subjects. Cunningham et al\[[@B194]\] analyzed the intracellular electrolyte composition of deltoid muscles in 7 normal subjects and 13 patients with various severe illnesses. Intracellular chloride concentration was 4.1 ± 1.5 mmol/L in the healthy subjects and 8.8 ± 3.6 mmol/L in the patients. Corresponding extracellular chloride concentrations were 104.4 ± 5.7 and 106.7 mmol/L respectively. Schober et al\[[@B195]\] measured TBW by ^3^H~2~O dilution and ECFV by radiobromide dilution in 10 normal subjects and 38 critically ill patients. TBW values were comparable between the two groups (536 ± 56 mL/kg in the healthy subjects and 505 ± 68 mL/kg in the critically ill patients). In contrast, bromide space as a fraction of body water was substantially higher in the critically ill patients (0.83 ± 0.17) than in the normal subjects (0.46 ± 0.04). These findings are consistent with substantially higher penetration of bromide into the intracellular compartment in critically ill patients than in normal subjects and raise serious concerns about the validity of ECFV measurements by bromide space in critically ill subjects.

The calculation of ECFV made by combining TBK and TBW values assumes that intracellular and extracellular potassium concentrations are constant, usually 152 and 4 mmol/L, respectively\[[@B136]\]. The equation for calculating ECFV is as follows: ECFV = (152 × TBW∣TBK)/148\[[@B136],[@B193]\]. Calculations of ECFV using this equation provided a reasonable agreement with calculations based on bromide space in the large number of subjects studied by Silva et al\[[@B193]\], with differences being more pronounced in obese subjects. ECFV calculations made using equations that combine TBW and TBK measurements will be subject to errors in subjects whose intracellular potassium concentration differs substantially from 152 mmol/L. Subjects with dystonicity in whom ECFV measurements may be required\[[@B184]\], have an abnormal intracellular potassium concentration. Certain categories of patients with severe illness, *e.g*., uremic patients, may also have low intracellular potassium concentration\[[@B196]\].

The principles and limitations of measurements of TBW and its compartments by BIA have been reviewed\[[@B61],[@B118],[@B167]\]. As stated above, BIA is widely used to investigate the status of body fluids in patients on dialysis. In patients undergoing hemodialysis, TBW measurements by BIA, which are used in the calculation of ECFV estimates, differed from ^2^H~2~O-based measurements by a margin of -3.4 to 20.3 L in one report\[[@B197]\]. Another report found gross underestimation of TBW by BIA in a hemodialysis patient with extreme ascites and hydrothorax\[[@B165]\]. In a study comparing measurements of TBW in hemodialysis patients by BIA and ^2^H~2~O, Chan et al\[[@B198]\] concluded that BIA either underestimates systematically TBW or overestimates systematically intracellular water and that the differences between reference and BIA measurements of TBW increase as comorbidities increase.

Another difficulty in measuring ECFV is establishing normal values. This process is complicated by various factors. In studies by Silva et al\[[@B136],[@B199]\], the fraction ECFV/TBW increased progressively with age in men, while both African American men and women had higher values of this fraction compared to subjects from other ethnic backgrounds. Several studies have confirmed that women have higher ECFV/TBW values in comparison to age-matched men\[[@B114],[@B200]-[@B202]\]. Children have substantially different ECFV/TBW values than adults\[[@B203]\], and obese children have higher ECFV/TBW values than non-obese children\[[@B151]\]. These facts underscore the need for establishing normal ECFV values that are specific for gender, age, ethnicity and degree of obesity.

The importance of estimates of ECFV in various disease states, the various methods that are available for measuring ECFV, and the limitations and costs of these methods create the need to choose the best method of measurement. Shepherd et al\[[@B204]\] compared recently various methods of analyzing body composition in terms of cost, compliance, infrastructure, precision, quality control, training, trueness, and safety. The major limitation of all methods for measuring ECFV is encountered during severe acute or chronic illnesses. Several illnesses lead to both hypervolemia producing clinical manifestations and uncertainty about the desired values of ECFV. For these reasons, the challenge of optimal ECFV in severe illness merits a separate analysis as a fluid balance concept and is addressed in the next section.

BODY FLUID BALANCE IN SEVERE CHRONIC OR ACUTE ILLNESS
=====================================================

Concept and principles of management of fluid balance in illness
----------------------------------------------------------------

Disturbances of body fluid balance are cardinal manifestations of many severe acute or chronic illnesses\[[@B205]\]. Precise management of these disturbances is critical\[[@B206]\]. Fluid management must address both repletion of deficits and avoidance of excesses\[[@B207]\] and requires understanding of the regulation and measurement of TBW and particularly ECFV. Adequate blood perfusion of organ systems is essential and is an indispensable role of ECFV. Normal cell function and survival require an uninterrupted supply of oxygen and nutrients, and removal of carbon dioxide and metabolic by-products. It has long been recognized that the optimal value of ECFV in critical illness may differ from a "normal" value\[[@B208]\]. The term "obligatory edema" was used in the past to denote the need for an expanded ECFV in patients with hepatic cirrhosis, ascites and hypoalbuminemia. The term "effective blood volume" was coined by Peters to indicate the need for supranormal blood volume in certain disease states\[[@B209],[@B210]\]. More recently, the term effective arterial blood volume (EABV) has been used to indicate the state of organ perfusion\[[@B95]\].

EABV is affected by several physiologic functions and biochemical parameters in addition to ECFV. Parameters related to either the composition of the blood, for example blood hemoglobin concentration and arterial blood gases, or the metabolic needs of diseased cells, are not directly correlated with ECFV. There are, however, several factors influencing EABV that interact directly with ECFV. Changes in these factors in disease states create the need for ECFV values that exceed normal values. Table [5](#T5){ref-type="table"} shows factors affecting organ perfusion that are interacting with ECFV\[[@B211],[@B212]\]. A brief discussion of these factors follows.

###### 

Factors affecting cell- and organ-perfusion (effective arterial blood volume)

  --------------------------------------
  Blood volume
  Red blood cell mass
  Plasma volume
  Cardiac output
  Vascular capacity
  Arterial resistance, total
  Arterial resistance, regional
  Venous capacity
  Starling forces in blood capillaries
  Endothelial barrier integrity
  Gravity
  --------------------------------------

ECFV directly defines the plasma volume. Schrier explored the interaction between cardiac function, arterial tone, and ECFV regulation as well as the factors affecting this relationship\[[@B213]\]. Starling forces in the blood capillaries and surrounding interstitial space dictate fluid exchanges between the intravascular and interstitial spaces. The importance of an effective capillary endothelial barrier to albumin transfer from the intravascular into the interstitial compartment is exemplified by patients who lose this barrier. Such patients require infusion of enormous volumes of albumin-containing fluid to maintain their intravascular volume\[[@B214]\].

The effects of gravity on EABV and ECFV were studied during space flights. Absence of gravity causes large transfer of fluids from peripheral body parts (*e.g*., limbs) into the central blood volume and decreases in the blood levels of vasopressin, renin and aldosterone, and causes profound diuresis of water and sodium salts\[[@B215]-[@B217]\]. Gravity and "head-out" water immersion have similar effects on EABV and ECFV\[[@B218]\]. This last observation may have clinical implications. The interactions between the factors indicated in Table [5](#T5){ref-type="table"} is the source of different optimal ECFV values in health and severe illness.

The aim of fluid management in severe illness is prevention of both organ hypoperfusion and circulatory overload. The methodology for evaluating EABV and determining whether clinical manifestations of low EABV are responding to volume replacement in critically ill patients is complex. The response of EABV to fluid challenges is monitored by a variety of invasive static (stroke volume, cardiac output, cardiac index) and dynamic (stroke volume variation, pulse pressure variation, change in the fraction "stroke volume"/"cardiac index") parameters\[[@B219]\]. The uses and limitations of the patient's history and clinical examination, chest X-ray and echocardiography, continuous dynamic evaluation of circulatory parameters during fluid administration, certain biochemical values, and BIVA in evaluating body fluid status were reviewed by Kalantari et al\[[@B207]\]. Adequate perfusion of the kidneys and prevention of acute kidney injury (AKI), which is both frequent in this clinical setting and an independent risk factor for mortality and prolonged hospital stay\[[@B220]-[@B222]\], is a main target of this fluid management. Fluid management efforts in critical illness should be directed towards the interactions of systemic and renal hemodynamics, the preservation of the renal microcirculatory blood flow\[[@B223]\], and the determination of indications for mechanical fluid removal\[[@B224]\].

The mechanisms that underlie fluid imbalance and their treatment vary depending on the nature of critical illnesses. Palmer et al\[[@B95]\] analyzed the general mechanisms leading to decreased EABV and target ECFV values that are higher than normal. These mechanisms include: Fluid trapping in the interstitium or a preformed body cavity; reduced serum oncotic pressure; and vascular disturbances, *e.g*., altered capillary filtration pressure due to low cardiac output, increased venous resistance, or endothelial dysfunction.

The clinical states discussed subsequently in this report illustrate the pathophysiologic mechanisms and the principles of fluid management in critically ill patients. The management of these conditions should address, in addition to ECFV, correction of abnormalities in the other factors specified in Table [5](#T5){ref-type="table"}. However, ECFV estimates made using traditional methods have a limited role in this management. The clinical states we have chosen to illustrate the concepts of fluid imbalance secondary to EABV disturbances in severe illness include congestive heart failure (CHF), hepatic cirrhosis, and sepsis. Finally, nephrotic syndrome represents a unique state of disturbed fluid balance. The pathogenesis of fluid imbalance in nephrotic syndrome involves both a reduced EABV and primary sodium salt retention by the kidneys. The mechanisms of volume retention in nephrotic syndrome will be discussed briefly.

Congestive heart failure
------------------------

Fluid retention characterizes the course of CHF, causes serious clinical manifestations, and is one of its main therapeutic targets. A decrease in cardiac output is the primary cause of fluid retention in CHF secondary to left ventricular failure (Table [5](#T5){ref-type="table"}). Palmer et al\[[@B95]\] reviewed the complex mechanisms sensing decreased EABV and the effector mechanisms of renal retention of salt and water in CHF. The Frank-Starling law of the heart states that the stroke volume increases as end-diastolic volume increases when all other factors affecting myocardial performance are unchanged\[[@B225]\]. In early-compensated stages of CHF, elevated left ventricular end diastolic volume secondary to both decreased cardiac performance and ECFV expansion leads to an increase in stroke volume and restoration of cardiac output. Figure [4](#F4){ref-type="fig"} compares the fraction ECFV/TBW in elderly subjects with relatively compensated CHF and healthy controls\[[@B226]\]. At this relatively early stage of CHF, ECFV/TBW was higher than normal. It is not clear whether the higher than normal ECFV in this stage of CHF is beneficial in the long term or not.

![The fraction extracellular volume over total body water in elderly subjects with relatively compensated congestive heart failure and healthy controls. Mean values ECFV/TBW in the study of Sergi et al\[[@B228]\]. The mean ejection fraction of elderly patients with relatively compensate congestive heart failure (CHF) and absence of pleural effusion was 40%. Total body water (TBW) was measured by ^2^H~2~O dilution and extracellular volume (ECFV) by bromide dilution. The fraction ECFV/TBW was significantly higher in subjects with CHF.](WJN-7-1-g004){#F4}

As CHF progresses, low EABV leads to progressive renal retention of salt and water\[[@B227]\], which causes ECFV expansion and progressive distention of the myocardium with adverse effects on cardiac performance\[[@B228]\]. Determining the optimal level of ECFV and maintaining the patient at that level are major management goals. Mechanisms of salt and water retention may differ between right and left ventricular failure\[[@B229]\]. Myocardial dysfunction in valvular disease and "high-output" cardiac disease represent other categories of CHF in which the optimal levels of ECFV may differ from those in left ventricular failure.

Fluid overload therapy can be insufficient in many patients hospitalized with CHF. Incomplete fluid removal during the hospital stay coupled with the limitations of weight-based management to identify the recurrence of fluid retention post discharge leads to symptomatic elevated intracardiac right and left-sided filling pressures. In these patients, vigorous and timely reduction of the elevated filling pressures leads to improved prognosis, fewer hospitalizations and better outcomes. However, prevention of both symptomatic ECFV expansion and lower than optimal ECFV in CHF is important. In dilated CHF, forward flow is optimal at near-normal filling pressures, with minimized mitral regurgitation\[[@B230]\]. In cases of acute CHF with persistent clinical manifestations, such as respiratory distress and impaired systemic perfusion, right heart catheterization is indicated. Fluid management must incorporate a thorough clinical patient evaluation, use of appropriate diuretics, frequent follow-up, and daily weight measurement\[[@B231]\]. Despite these measures, re-admissions are not prevented; thus, multiple approaches for monitoring outpatient fluid balance are being explored.

Natriuretic peptide biomarkers (BNP, B-type natriuretic peptide, NT-pro-BNP, N-terminal pro-B-type natriuretic peptide) are increasingly being used to diagnose and estimate the severity of CHF as well as for population screening purposes. Many other biomarkers have been implicated in CHF (markers of inflammation, oxidative stress, vascular dysfunction, and myocardial and matrix remodeling). Furthermore, biomarkers of myocardial fibrosis, soluble ST2 receptor, and galectin-3 are predictive of hospitalization and death and may provide supplemental prognostic value to BNP levels in patients with CHF\[[@B231]\]. All these biomarkers have been used in assessing fluid balance status in patients with CHF.

BIVA has also been applied in assessing fluid balance status in patients with CHF\[[@B130]\]. Valle et al\[[@B232]\] tested the hypothesis that achievement of adequate ECFV status with intensive medical therapy, modulated by combined BIVA and BNP measurement, optimizes the timing of discharge and improves the clinical outcomes of patients admitted with acutely decompensated heart failure (ADHF). Three hundred patients admitted for ADHF underwent serial BIVA and BNP measurements. Therapy was titrated to reach a BNP value \< 250 pg/mL. Patients were categorized as early responders (rapid BNP fall below 250 pg/mL); late responders (slow BNP fall below 250 pg/mL, after aggressive therapy); and non-responders (BNP persistently \> 250 pg/mL). Worsening of renal function was evaluated during hospitalization. Death and re-hospitalization were monitored with a 6-mo follow-up. This study confirmed the hypothesis that serial BNP/BIVA measurements help to achieve adequate fluid balance status in patients with ADHF and can be used to drive a "tailored therapy", allowing clinicians to identify high-risk patients and possibly to reduce the incidence of complications secondary to fluid management strategies.

The combined use of BNP and BIVA for assessing and managing fluid overload, distinguishing cardiogenic from non-cardiogenic dyspnea, and improving management of CHF patients in Emergency Departments was tested in another report as well\[[@B233]\]. This randomized controlled trial was designed to investigate whether fluid status monitoring with an automatically generated wireless CareAlert notification can reduce all-cause death and cardiovascular hospitalizations in a CHF population, compared with standard clinical assessment\[[@B234]\]. The investigators found that fluid status telemedicine alerts did not significantly improve outcomes in patients with advanced CHF and implantable cardioverter defibrillators (ICDs). The problem of adherence to treatment protocols by physicians and patients might be compromising advances in the telemedicine field\[[@B235]\].

The term Cardio-Renal Syndrome (CRS) defines disorders of the heart and kidneys whereby "acute or chronic dysfunction in one organ may induce acute or chronic dysfunction of the other"\[[@B236]\]. CRS requires a tailored approach to manage a patient's underlying pathophysiology while optimizing the patient's clinical picture and thus providing better outcomes. Precise prescription of fluid removal by diuretics or extracorporeal therapies is a key element of this approach. Adequate monitoring of fluid balance is essential for preventing worsening of renal function or other complications while delivering these therapies. Monitoring of extravascular fluid in the lungs by ultrasonography is helpful in fluid management\[[@B237]\]. The range of optimal ECFV values appears to be very narrow in patients with CHF. Hypervolemia results in myocardial stretching and decompensation, whereas hypovolemia leads to low EABV that can result in organ damage. Therefore, in cases with CRS the "5B" approach has been suggested: Balance of fluids (reflected by body weight), blood pressure, biomarkers, BIVA, and blood volume\[[@B236]\].

It has traditionally been presumed that patients with CHF benefit from a low-sodium diet. A recent review attempted to provide insight into the currently available evidence base for the effects of dietary sodium restriction in patients with chronic CHF. This review concluded that both observational and experimental studies have shown mixed results and that the effects of a low-sodium diet on clinical outcomes in patients with CHF remain controversial and unclear\[[@B238]\]. However, the fact remains that most hospitalizations for CHF are related to sodium and fluid retention. Recent research suggests that not all sodium is distributed in the body solely as a free cation, but that some sodium is also bound in different tissues to large interstitial GAG networks that appear to have important regulatory effects on ECFV. In CHF, high sodium intake and neurohumoral alterations disrupt GAG structure, leading to loss of the interstitial buffer capacity for sodium and disproportionate interstitial fluid accumulation. Moreover, a diminished GAG network increases vascular resistance and interferes with endothelial nitric oxide production. Improved imaging modalities should help in the assessment of interstitial sodium levels and endothelial glycocalyx integrity. Furthermore, several therapies have been proven to stabilize interstitial GAG networks, *e.g*., hydrocortisone, sulodexide, dietary sodium restriction, spironolactone). Hence, better understanding of this new sodium "compartment" might improve the management of CHF\[[@B239]\].

Detailed guidelines for the diagnosis and treatment options of the various forms of CHF (acute or chronic, with reduced or not-reduced ejection fraction) are available\[[@B231],[@B240]\]. The patient who presents with suspected CHF should be assessed by clinical history and detailed physical examination. Chest X-ray, electrocardiogram and blood levels of natriuretic peptides are always useful. The next step is an echocardiogram. If CHF is confirmed, its etiology should be determined and appropriate treatment initiated. At the end of these guidelines the authors discuss the missing pieces of information in the existing literature and offer thoughtful recommendations for future work. Since there is no exact method for estimating optimal ECFV in patients with CHF, future studies should address this knowledge gap.

Cirrhosis-ascites-hepatorenal syndrome
--------------------------------------

Decreased EABV is a cardinal feature of cirrhosis in which changes in multiple factors activate the mechanisms of sodium retention and ECFV expansion. Factors that lead to decreased EABV in cirrhosis are listed in Table [5](#T5){ref-type="table"} and include: Increase in overall arterial and venous capacity, decrease in Starling forces, and, in late stages of cirrhosis, decrease in cardiac output. The decrease in arterial and venous resistance is a strong stimulus for increased ECFV. Advanced cirrhosis is characterized by portal hypertension, arteriovenous fistulae, peripheral vasodilatation, and sequestration of plasma volume in the abdominal cavity and splanchnic venous bed\[[@B241]\]. The "arterial vasodilation theory" is the most widely accepted explanation for the expansion of ECFV in cirrhotic patients\[[@B242]\]. An alternative theory, designated the "hepatorenal reflex hypothesis", suggests that vascular bed vasodilatation in cirrhosis is a consequence of the shunting of blood from the portal to the systemic circulations rather than an etiology for volume overload; however, further research is required to support this hypothesi\[[@B243]\].

The widely recognized causes of vasodilatation in cirrhosis are: (1) Increased production or increased activity of vasodilating factors by hepatocytes and stellate cells (mainly nitric oxide, carbon monoxide, prostacyclin and endogenous cannabinoids); (2) reduced response to vasoconstrictor factors; (3) mesenteric neoangiogenesis; (4) compromise of cardiac output as cirrhosis progresses probably due to cirrhotic cardiomyopathy; and (5) systemic inflammatory response with increased production of pro-inflammatory cytokines (IL-6, TNF-α) and vasodilating factors due to translocation of bacteria and their products across the intestinal barrier to mesenteric lymph nodes\[[@B244]-[@B247]\]. In addition, markers of oxidative stress such as oxidized albumin have been shown to increase in decompensated cirrhosis\[[@B242]\]. The exact cellular and molecular mechanisms implicated in the phenomenon of bacterial translocation in cirrhosis have not been fully elucidated\[[@B246]\]. Hypoalbuminemia, another feature of advanced cirrhosis, decreases intracapillary colloid-osmotic forces and increases fluid translocation from the intravascular into the interstitial compartment leading to further decreases in EABV. Circulatory abnormalities in cirrhosis define the stages of progression of cirrhosis that ultimately culminate in hepatorenal syndrome (HRS). Cardiac output is not a cause of clinical manifestations in early compensated stages, but is increased in advanced cirrhosis, and may decrease in its later stages and thus contribute to the decreased EABV. Cirrhotic vasodilatation stimulates the arterial stretch receptors in the carotid sinus and aortic arch, producing a baroreceptor response and activation of compensatory vasoconstricting mechanisms including the renin-angiotensin-aldosterone system, the sympathetic nervous system, and the non-osmotic hypersecretion of vasopressin\[[@B248]\]. Stimulation of these systems contributes to maintenance of blood pressure by modulating decreases in the systemic vascular resistance and increasing cardiac output\[[@B248]\].

The so-called "hyperdynamic syndrome" in cirrhosis is a consequence of portal hypertension and involves complex humoral and neural mechanisms. This syndrome is hemodynamically characterized by high cardiac output, increased heart rate and total blood volume, reduced total systemic vascular resistance and normal or decreased blood pressure\[[@B245]\]. Arterial blood volume is shunted to the splanchnic vessels at this stage, while the central arterial blood volume (heart, lungs, and central arterial tree blood volume) is often decreased\[[@B245]\]. At a later stage, the hyperdynamic syndrome leads to cardiac dysfunction (cirrhotic cardiomyopathy), pulmonary dysfunction (hepatopulmonary syndrome) and renal dysfunction (HRS), in addition to reduced survival\[[@B249]\].

The function of the cardiovascular system is disturbed in cirrhosis due to decreased vascular reactivity and a universal endothelial and autonomic dysfunction\[[@B249]\]. Cirrhotic cardiomyopathy is characterized by impaired myocardial contractility with systolic and diastolic dysfunction in combination with electromechanical abnormalities, such as prolongation of the Q-T interval, in the absence of any other cardiac disease\[[@B249]\]. Some degree of diastolic dysfunction may be present in \> 50% of cirrhotic patients regardless of the presence or extent of ascites. No correlation has been found between HRS and diastolic dysfunction\[[@B242]\]. A study of the role of cardiac abnormalities in the pathogenesis of circulatory and renal dysfunction in cirrhosis\[[@B250]\] concluded that: (1) Diastolic dysfunction is frequent, but mild in most cases and does not increase the pulmonary artery pressure to abnormal levels. This may be due to the central hypovolemia of cirrhosis and probably accounts for the lack of symptoms associated with this condition; (2) diastolic dysfunction is unrelated to circulatory dysfunction and ascites; and (3) in cirrhosis, there is a lack of response of the left ventricular systolic and chronotropic function to peripheral arterial vasodilatation and activation of the sympathetic nervous system. This feature is an important contributory factor to the progression of circulatory dysfunction and the pathogenesis of HRS, which constitutes the last stage of the circulatory disturbances in cirrhosis\[[@B244],[@B247],[@B248]\]. Other systems are affected as well including: The femoral and brachial vessels (producing cramps), the immune system, the adrenal glands, and the vessels in the brain (playing a role in encephalopathy)\[[@B247],[@B249]\].

The vasoconstrictive compensation in cirrhosis includes the renal vessels and negatively affects renal function, resulting in sodium and solute-free water retention, edema, and eventually renal failure. Patients with advanced cirrhosis exhibit a shift in the renal autoregulation curve, which means that for a given level of perfusion pressure, renal blood flow is lower compared to that of patients with compensated cirrhosis; a decrease in GFR leading to HRS ensues. HRS is almost exclusively of a functional nature and usually without discernable histologic abnormalities in the kidneys\[[@B242],[@B245]\]. However, in some reports the kidneys of cirrhotic patients with presumed HRS showed histologic evidence of AKI. Immunologic mechanisms are apparently important in mediating the renal injury and hemodynamic factors do not operate in isolation\[[@B251]\].

HRS is classified into two subgroups, HRS 1 and HRS 2. The rate of deterioration of renal function is rapid, within 2 wk, in HRS 1 and slower in HRS 2, occurring over several months\[[@B244]\]. HRS must routinely be differentiated from two other conditions that cause AKI frequently in cirrhotic patients, namely acute tubular necrosis and prerenal azotemia. AKI in cirrhosis carries a high risk for mortality\[[@B252]\], with HRS or acute tubular necrosis having substantially higher mortality rates compared to prerenal azotemia\[[@B252]\]. Urinary biomarkers can be helpful in differentiating between HRS and acute tubular necrosis. Urinary neutrophil gelatinase-associated lipocalin (NGAL) activity was shown to be highly accurate in identifying patients with acute tubular necrosis and was incorporated into a proposed diagnostic algorithm\[[@B253]\]. Other biomarkers that were shown to be useful in the diagnosis of acute tubular necrosis include interleukin-18 (IL-18), albumin, trefoil-factor-3 (TFF-3) and glutathione-S-transferase-π (GST-π)\[[@B253]\].

NGAL is not helpful in differentiating between pre-renal azotemia and HRS\[[@B247]\]. Also, biochemical analytes indicative of tubular function do not distinguish between prerenal azotemia and HRS; in both conditions, the decrease in GFR is associated with intact tubular function as reflected by a very low urinary sodium concentration and high urine to plasma (U/P) creatinine ratio. The response of renal dysfunction to expansion of the intravascular space with colloid or saline solutions constitutes the key differentiating feature between the two conditions. Prerenal azotemia is reversed with adequate fluid replacement and no other measures. In contrast, reversal of HRS requires administration of fluid plus vasoconstrictors.

In addition to pre-renal azotemia and acute tubular necrosis due to hypovolemia (bleeding, diarrhea, excessive use of diuretics), several other clinical conditions may cause AKI in patients with advanced cirrhosis. These conditions include: (1) Bacterial infections with or without septic shock (such as spontaneous bacterial peritonitis); (2) use of nephrotoxic medications such as non-steroidal anti-inflammatory drugs or aminoglycosides; (3) abdominal compartment syndrome from tense ascites; and (4) intrinsic renal diseases (hepatitis-B or C associated glomerulonephritis, glomerulonephritis in alcoholic cirrhosis)\[[@B240],[@B244],[@B252]\]. The initial management of cirrhotic patients with AKI should address all these conditions. This management is therefore complex, but depends primarily on accurate assessment of the status of EABV. Physical examination and invasive measurements, such as central venous pressure, often do not reflect intravascular volume status. Point-of-care echocardiography can be effective in guiding the timing of large volume abdominal paracentesis and optimizing the hemodynamic status in decompensated cirrhotic patients with AKI, which in turn can improve venous return and promote recovery of renal function\[[@B254]\].

First-line treatment of patients with cirrhosis and ascites consists of sodium restriction and application of diuretics. However, the main thrust for preventing and managing HRS is directed towards expanding ECFV with albumin infusions and correcting the splanchnic vasodilatation by vasoconstrictors, including octreotide, sympathomimetic agents (*i.e*., midodrine), and vasopressin analogues (*i.e*., terlipressin). Oral midodrine has been shown to improve clinical outcomes and survival in patients with refractory ascites\[[@B255]\]. In patients with stable hypotension, midodrine may improve splanchnic and systemic hemodynamic variables, renal function, and sodium excretion. In patients without HRS, midodrine was shown to increase urinary volume, urinary sodium excretion, and mean arterial pressure and was associated with a reduction in overall mortality\[[@B256]\].

Terlipressin and albumin administration can reverse HRS and reduce the associated short-term mortality rate\[[@B257],[@B258]\]. Terlipressin alone is effective in reversing HRS in a smaller number of patients (40%-50%). In the REVERSE study, terlipressin plus albumin was associated with greater improvement in renal function *vs* albumin or terlipressin alone in patients with HRS-1, whereas rates of HRS reversal were similar with terlipressin or albumin alone\[[@B259]\].

Based on four small studies, norepinephrine appears to be an attractive alternative to terlipressin in the treatment of HRS, in part because it is associated with fewer adverse events\[[@B260]\]. Infusion of albumin plus norepinephrine may be beneficial in HRS 1\[[@B255]\]. Albumin has dose-dependent effects in both increasing survival and reducing complications in cirrhotic patients with HRS\[[@B261]\]. The beneficial effects of albumin infusion are not due solely to its oncotic properties. In patients with advanced cirrhosis, several albumin functions, such as binding of toxins, drugs and drug metabolites, are depressed because of molecular alterations of the compound, *e.g*., to oxidized albumin. Replacement of the altered albumin molecules by the infused albumin has beneficial effects\[[@B262]\]. Predictors of the clinical response to terlipressin and albumin treatment are the serum bilirubin and creatinine levels along with the increase in blood pressure and the presence of systemic inflammatory response syndrome\[[@B258]\].

Another approach to the management of HRS, namely "head-out" water immersion, has confirmed the importance of low EABV in this syndrome. Two studies have investigated water immersion as a means of increasing central blood volume in patients with HRS\[[@B241],[@B263]\]. In both studies, water immersion resulted in marked natriuresis and diuresis, and a decrease in plasma levels of renin and aldosterone. In the study by Bichet et al\[[@B241]\], although a five-hour water immersion in one patient with HRS resulted in central blood volume expansion and a modest decrease in serum creatinine concentration, it did not reverse the HRS. In a study by Yersin et al\[[@B263]\], two patients with HRS underwent repeated two-hour daily courses of water immersion for a week; in both patients, significant decreases in serum creatinine concentration were noted.

In a recent therapeutic algorithm for HRS 1, the use of the combination of octreotide, midodrine and albumin without vasoconstrictors was discouraged because of low efficacy\[[@B255]\]. The use of vasopressin for the treatment of HRS-1 was also not recommended, due to several adverse effects and the lack of randomized, clinical trials supporting this use\[[@B257]\]. Other treatments for HRS have also been assessed and include dopamine, transjugular intrahepatic portosystemic shunt, and renal and liver replacement therapy. However, current thinking is that liver transplantation in the only curative option and should be considered in all patients\[[@B247],[@B257]\].

The evaluation of EABV in patients with cirrhosis, especially with regard to the differential diagnosis of AKI, is based on their response to infusion of albumin and vasopressors. Traditional laboratory techniques have also been employed for the evaluation of the status of fluid balance in these patients. The BNP and its prohormone (pro-BNP) are elevated in patients with cirrhosis as well as those with CHF, thereby rendering it difficult from a single plasma BNP measurement to accurately differentiate between ascites due to CHF and ascites due to cirrhosis\[[@B264]\]. Elevated plasma BNP confirms CHF with high probability, but is of limited value in evaluating EABV in cirrhosis\[[@B265],[@B266]\].

Methods evaluating body composition have also been employed for evaluating fluid balance status in cirrhotic patien. BIA studies have been employed in evaluating the volume of the ascetic fluid\[[@B267]\] and the changes in ECFW/TBW in various parts of the body as cirrhosis progresses\[[@B267],[@B268]\]. Further work is needed to evaluate the role of body composition analysis in assessing fluid balance in cirrhotic patients.

CHF and cirrhosis both usually cause ECFV expansion. Whether a modest degree of ECFV expansion is beneficial in early compensated stages of CHF has yet to be determined. ECFV expansion is deleterious in advanced stages of CHF; however, a modest degree of ECFV expansion appears to be beneficial in cirrhosis. The treatment of advanced cirrhosis, especially HRS, is based on further ECFV expansion by means of albumin-containing solutions. ECFV levels optimal for these conditions remain to be established. In addition to ECFV excesses, both advanced CHF and advanced cirrhosis are often associated with relative water excess leading to hypotonic hyponatremia. Unlike hypervolemia, which at least in cirrhosis may have beneficial effects, hyponatremia is an independent predictor of adverse outcomes in both CHF\[[@B269],[@B270]\] and cirrhosis\[[@B271]\]. Current management guidelines call for aggressive treatment of hyponatremia in both clinical conditions\[[@B82]\].

Sepsis
------

The definition of sepsis and the methods for determining its degree of severity have undergone changes recently. Two degrees of severity are currently recognized, namely sepsis and septic shock. The older degree "severe sepsis" was deemed redundant. Sepsis is defined as life-threatening organ dysfunction secondary to a response to infection involving both pro-inflammatory and anti-inflammatory immunological responses and reactions in non-immunological cardiovascular, neuronal, hormonal, metabolic, bio-energetic, and coagulation pathways\[[@B272]\]. Septic shock is a subset of sepsis characterized by profound circulatory, cellular, and metabolic abnormalities and a heightened mortality risk\[[@B272]\]. Severe hypotension and greatly elevated serum lactate levels are the defining criteria of septic shock.

Sepsis accounts for about 2% of all hospital admissions and 10% of intensive care unit (ICU) admissions in the United States\[[@B273]\]. Several organ systems develop severe dysfunction during sepsis, the respiratory and cardiovascular systems being the most commonly affected. Other frequently affected organ systems include: The central nervous system, kidneys, peripheral nervous system, muscles, gastro-intestinal tract, and thyroid gland\[[@B273]\]. The development of AKI in sepsis is associated with a 70% mortality rate\[[@B274]\].

The pathogenesis of sepsis involves different mechanisms that have been investigated by various teams of researchers\[[@B272]-[@B274]\]. Unraveling these mechanisms has led to novel strategies, some of which are still in the research stage, for managing sepsis\[[@B275]\]. In this review, we focus on fluid balance issues. Sepsis causes profound disturbances in at least three of the determinants of EABV listed in Table [5](#T5){ref-type="table"}: Vascular capacity, cardiac output, and capillary endothelial barrier. Sepsis can be considered as the prototype of an acute illness causing life-threatening decreases in EABV. In sepsis, ECFV values above the normal range are associated with favorable outcomes.

Increased vascular capacity is a primary cause of low EABV in sepsis. Pro-inflammatory cytokines released in sepsis cause arterial vasodilatation and decrease peripheral vascular resistance. Several metabolic pathways mediate vasodilatation. Upregulation of the inducible nitric oxide synthase and profound release of nitric oxide is a potent vasodilatory pathway\[[@B274]\]. Vasodilatation is manifested primarily in the splanchnic vascular bed, the muscles and the skin, while the renal vascular bed exhibits vasoconstriction\[[@B274]\]. Compensatory mechanisms for vasodilatation include activation of the sympathetic nervous system and the renin-angiotensin-aldosterone axis, release of vasopressin, and increase in cardiac output\[[@B274]\]. Renal vasoconstriction results from high levels of the compensatory hormones which include catecholamines and vasopressin.

One of the mechanisms for compensating for low EABV in sepsis is an increase in cardiac output. However, cardiac output may be depressed in severe septic episodes leading to decreased ejection fraction in approximately 50% of the cases\[[@B276]\]. Studies in a murine model also revealed adverse effects of sepsis on heart rate, heart rate variability and electrical impulse conduction\[[@B277]\]. Reversal of cardiac dysfunction in sepsis survivors after several days suggests that the mechanism of dysfunction was functional rather than structural\[[@B276],[@B278]\]. However, structural cardiac abnormalities, including mononuclear cell infiltrates, edema, fibrosis, disruption of mitochondria, myocardial cell death and apoptosis were found in the hearts of humans or experimental animals dying from sepsis\[[@B279]\]. A variety of mechanisms leading to myocardial dysfunction in sepsis have been proposed\[[@B276],[@B278],[@B279]\]. Therapeutic interventions directed to specific mechanisms are at the stage of pre-clinical trials in experimental sepsis models\[[@B280]\].

Disruption of the blood capillary endothelial barrier is the third major mechanism leading to low EABV in sepsis. Starling forces regulate fluid transfers between the intravascular and interstitial compartment and play an important role in the maintenance of the intravascular blood volume and EABV. In animal studies reviewed by Schrier and Wang\[[@B274]\], vasodilatation caused albumin and fluid transfer from the intravascular into the interstitial compartment. Generalized capillary protein leakage was documented in septic patients by Ishihara and coinvestigators\[[@B281]\]. The endothelial barrier defect is not the exclusive result of arterial vasodilatation. A variety of mediators of endothelial barrier damage in sepsis, including the complement components Ca and C5a, bradykinin, platelet activating factor (PAF), pro-inflammatory cytokines, and many others have been identified\[[@B282],[@B283]\]. Endothelial barrier disruption is considered a key step in the development of septic shock\[[@B283]\].

Collectively, vasodilatation, myocardial dysfunction, and impairment of the endothelial barrier lead to decrease in EABV and render imperative the need for administration of large volumes of fluid and vasoconstrictors, which are mainstays of treatment in sepsis. However, impaired cardiac and endothelial barrier function increase the risks of fluid administration in septic patients\[[@B274],[@B284]\] and narrow its therapeutic margins. Recent therapeutic trials and meta-analyses\[[@B285]-[@B294]\] have addressed the issue of the volume of fluids administered to septic patients among other issues.

A prospective randomized trial of aggressive treatment by infusion of fluids based on invasive monitoring of central venous pressure in septic patients prior to their admission to the ICU showed advantages in survival and improvement in important biochemical parameters including central pressure oxygen saturation, serum lactate concentration and metabolic acid-base values\[[@B285]\]. Subsequently, three large prospective randomized studies compared goal-directed early (pre-ICU) resuscitation and routine management of septic shock\[[@B286]-[@B288]\]. In all three studies, patients assigned to early goal-directed care routinely received larger volumes of fluids and higher doses of vasoconstrictors than those assigned to routine care. No difference in mortality and most other secondary outcomes was noted between the treatment groups in any of these studies; however, one study computed a higher cost for the early, goal-directed group of patients\[[@B288]\]. A meta-analysis of 11 randomized trials concluded that early-goal directed therapy for septic shock is not associated with early (28 d) or late (90 d) mortality improvement\[[@B289]\].

Fluid balance during treatment of sepsis or septic shock was addressed in three recent reports. One study found no difference in volume of fluid gained during treatment of septic shock between surviving and deceased patients\[[@B290]\]. The second study found significantly lower mortality in patients with sepsis or septic shock receiving less than 5 L than in those receiving more than 5 L of fluids in the first day of treatment and an increase in mortality by 2.3% for each liter of administered fluid in excess of 5 L\[[@B291]\]. The third study analyzed risks for mortality from sepsis associated with a completion within three hours of a protocol calling for blood cultures, administration of antibiotics and administration of 30 mL of crystalloids per kilogram. This study reported an increased risk for longer waiting until administration of antibiotics, but not for longer time to completion of the fluid bolus\[[@B292]\].

Finally, two randomized studies addressed two other issues related to fluid balance and EABV during treatment of septic shock. The first study found similar mortality rates in patients with targeted mean arterial blood pressure of 80 to 85 mmHg and those with targeted pressure of 60 to 65 mmHg\[[@B293]\]. Mean fluid volume administration was similar in the two groups while the higher blood pressure group received higher doses of norepinephrine and for a longer time. The second study found similar mortality rates in patients with targeted blood hemoglobin level above 9 g/dL and those with targeted level above 7 g/dL\[[@B294]\]. The international guidelines for management of sepsis and septic shock recommend a minimal initial intravenous crystalloid fluid bolus of 30 mL/kg within the first three hours followed by additional fluid administration guided by hemodynamic monitoring and maintenance of mean arterial blood pressure above 65 mmHg by vasoconstrictors as needed\[[@B295]\]. The guidelines highlight all three recommendations as "strong" and the quality of evidence as "weak" for the first recommendation, "best practice evidence" for the second and "moderate" for the third.

Infusion of large volumes of fluid is one of the key therapeutic modalities in sepsis and septic shock; however, the literature provides ample evidence indicating that the safety margin of fluid infusion in sepsis is narrow. The optimal level of volume expansion will need further research to be determined. The need for volume replacement in sepsis is not determined by measurements of ECV, but by clinical, laboratory and hemodynamic criteria. Calculation of blood volume, by adding plasma volume measurements obtained by dilution of injected albumin labelled with radioactive iodine (^131^I-albumin) and red cell mass computed from either hematocrit and plasma volume \[Blood volume = plasma volume/(1∣Hematocrit)\], or measured simultaneously with plasma volume by injected red blood cells (RBCs) labelled with radioactive chromium (^51^Cr-RBC) has found wider application than the measurement of TBW or ECV in critically ill patients with conditions leading to blood loss\[[@B296],[@B297]\].

Nephrotic syndrome
------------------

Heavy albuminuria, hypoalbuminemia and pronounced salt retention leading to ECFV expansion and edema, but typically not to hypertension, characterize the nephrotic syndrome. The cardinal complaint of patients suffering from nephrotic syndrome is edema\[[@B298]\]. The pathogenesis of edema formation has been disputed\[[@B299]\]. Two theories, the underfill and overflow or overfill theories, explaining the fundamental mechanism of salt retention and edema formation in nephrotic syndrome have been proposed\[[@B300],[@B301]\]. The underfill theory places the focus of salt retention on the nephrotic hypoalbuminemia which causes through Starling forces decreased blood volume and EABV and stimulation of neurohumoral pathways leading to renal salt and water retention\[[@B300],[@B302]\]. A subset of patients with severe nephrotic syndrome and profound hypoalbuminemia exhibit elevated serum levels of indicators of hypovolemia, including vasopressin, renin, aldosterone and norepinephrine; "head-out" water immersion of nephrotic patients with these features resulted in pronounced natriuresis and diuresis and substantial decreases in the levels of all four indicators of hypovolemia\[[@B303]\]. Decreases in interstitial colloid-osmotic pressure accompanying decreases in plasma albumin concentration and colloid-osmotic pressure modulate the loss of intravascular fluid into the interstitial compartment in nephrotic syndrome\[[@B304]\].

The overflow theory states that patients with nephrotic syndrome have an expanded plasma volume, and that the retention of sodium leading to edema formation in these patients is the result of an intrinsic defect in renal salt excretion. The first evidence against the underfill theory was provided by Meltzer et al\[[@B305]\] who noticed that serum renin and aldosterone levels were not elevated in a subset of patients with nephrotic syndrome. Other important observations arguing against the underfill theory include the following: (1) Animals and humans with congenital analbuminemia rarely develop edema\[[@B306],[@B307]\]; (2) blood volume is increased in a subset of edematous patients with the nephrotic syndrome\[[@B308]\]; (3) volume expansion with hyperoncotic albumin in edematous patients with nephrotic syndrome and various underlying renal histologic pictures, including minimal change disease, results in normal suppression of plasma renin activity and aldosterone, without significantly increasing urinary sodium excretion\[[@B309]\]; (4) medications blocking the renin-angiotensin-aldosterone system (RAAS), such as angiotensin-converting enzyme (ACE) inhibitors, do not increase natriuresis in nephrotic patients\[[@B310]\]; (5) adrenalectomy does not prevent edema formation in laboratory animals with nephrotic syndrome\[[@B311]\]; and (6) natriuresis in the recovery phase of nephrotic syndrome in children starts before serum albumin is normalized\[[@B312]\]. These observations suggested that the renal retention of sodium salts in some patients with nephrotic syndrome results not from low EABV, but from a primary renal retention of sodium\[[@B313],[@B314]\].

Ichikawa et al\[[@B315]\] reported primary renal retention of salt in a unilateral model of puromycin-induced nephrotic syndrome in rats. Subsequently, Kim et al\[[@B316]\] demonstrated increased expression and apical targeting of the epithelial sodium channel (ENaC) in the distal convoluted tubule, connecting tubule, and collecting duct of rats with puromycin-induced nephrotic syndrome. Increased synthesis of the sodium-potassium ATPAse (Na,K-ATPase) was also observed in the collecting ducts of rats with puromycin-induced nephrotic syndrome\[[@B317]\]. Serine proteases, which are present in high concentrations in the glomerular filtrate of nephrotic patients, play a major role in the activation of ENaC by cleaving certain channel-protein subunits and removing certain inhibitory peptides from the channel thus increasing its open probability\[[@B318]\]. A landmark study by Svenningsen et al\[[@B319]\] showed that urine from laboratory animals and patients with nephrotic syndrome can activate ENaC and promote sodium retention. In this study, mass-spectrometry analysis identified plasmin, an abnormally filtered enzyme, as the serine protease responsible for ENaC activation.

The widely accepted current view is that sodium retention develops in all subtypes of the nephrotic syndrome because of ENaC activation in the collecting ducts regardless of EABV\[[@B320],[@B321]\]. Other mechanisms, including a proposed increase in the permeability of blood capillaries\[[@B321],[@B322]\], decrease in the renal response to atrial natriuretic peptide (ANP), decreased conversion of pro-ANP to ANP in the kidneys, and decreased expression of nitric oxide synthase in the kidneys\[[@B323]\], are also likely contributors to salt retention and edema formation in the nephrotic syndrome. Underfilling represents an additional mechanism of edema formation in some nephrotic patients\[[@B314]\]. Hypovolemia and underfilling are pronounced in nephrotic subjects with very low serum albumin levels, *e.g*., children with minimal change disease\[[@B323]\]. BIA studies have been employed in assessing fluid balance in patients with the nephrotic syndrome\[[@B324]-[@B326]\]. Figure [5](#F5){ref-type="fig"} shows changes in EABV and ECF in the chronic conditions, including CHF, cirrhosis and nephrotic syndrome, discussed in this report.

![Percent changes from normal of body fluid compartments in hypervolemic states. I: Normal body fluid state; II: Congestive heart failure, hepatic cirrhosis, nephrotic syndrome with underfill mechanism of fluid retention; III: Nephrotic syndrome with overfill mechanism of fluid retention. EABV: Effective arterial blood volume; ECFV: Extracellular fluid volume; TBW: Total body water.](WJN-7-1-g005){#F5}

CONCLUSION
==========

The traditional concepts of body fluid balance encompass the regulation and perturbations of the relation between TBW and effective body solute (tonicity), and the regulation, measurement, and disturbances of ECFV. Severe acute and chronic illnesses cause disturbances that affect both fluid balance concepts. However, while the disturbances in tonicity have always adverse effects and require aggressive treatment, modest excesses in ECFV can be beneficial in some illnesses (*e.g*., cirrhosis, sepsis) and represent targets of the fluid management. The optimal ECFV in these illnesses is greater than the normal ranges of ECFV in healthy individuals because disease states produce changes in several factors that interact with ECFV in regulating EABV. These other factors are subjects of intense research and constitute therapeutic targets along with fluid treatment of ECFV. It is important to distinguish between fluid retention that results from low EABV, as in CHF or cirrhosis, and fluid retention that results from either low EABV or primary renal salt and water mechanisms, as in nephrotic syndrome. The traditional methods for measuring ECFV are associated with greater sources of error in patients with severe illness than in normal individuals. The management of fluid balance in patients with severe illness clearly needs further research. Two key questions regarding fluid balance should be addressed in these patients: (1) Are factors other than ECFV affecting EABV (Table [5](#T5){ref-type="table"}) disturbed causing, in addition to the need for their proper management, the need for ECFV values different from the normal values? (2) If fluid retention is a feature of these illnesses, is it a consequence of decreased EABV from a disturbance of the factors shown in Table [4](#T4){ref-type="table"} or of primary renal retention of salt? For these reasons, severe illness with fluid disturbances justifies a separate concept of body fluid balance.
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